Oncology Learning Network® is an online resource for the latest updates in oncology practice. Official digital home for @OLNGreatDebates and @LLMCongress.
Joined April 2018
- Tweets 3,119
- Following 414
- Followers 1,138
- Likes 779
2,401 Photos and videos
Breaking News: Based on results from the #CAPItello281 trial, the @US_FDA has approved #capivasertib (@AstraZeneca) plus #abiraterone and #prednisone for #PTEN-deficient metastatic hormone-sensitive prostate cancer. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
58
Phase 2 data show #fedratinib demonstrated promising clinical activity in #MDS/#MPNs and chronic neutrophilic #leukemia. Learn more: hubs.ly/Q04lc9sL0
#onctwitter #medtwitter
1
41
Breaking news: Based on results from the phase 3 LITESPARK-022 trial, the @US_FDA has approved adjuvant belzutifan plus pembrolizumab for adult patients with clear cell renal cell carcinoma at intermediate- or high risk of recurrence. Learn more: hmpgloballearningnetwork.com…
36
Phase 2 data show autologous #NKcell consolidation significantly improved survival in limited-stage #SCLC after firstline #chemoradiotherapy. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
42
Scott Kopetz, MD, PhD, FASCO, discusses updated #BREAKWATER Cohort 3 findings supporting #encorafenib plus #cetuximab and #FOLFIRI as a first-line option for #BRAF #V600E–mutant #mCRC. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
33
Updates from #EHA26: Updated results from a phase 1a/1b study show that #bexobrutideg continues to demonstrate strong clinical promise in patients with #CLL and #SLL. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
67
The @US_FDA has approved an orally disintegrating formulation of #nilotinib (@CyclePharma) for adults with Ph–positive #CML that can be administered with acid-reducing agents and without food restrictions. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
50
The phase 3 #KEYNOTED46/#EVOKE03 trial has been discontinued after sacituzumab govitecan plus #pembro failed to achieve a statistically significant #PFS benefit in previously untreated metastatic #NSCLC. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
69
In this APP Institute case presentation, Mary Steinbach, NP, discusses extramedullary progression after CAR-T therapy in a patient with high-risk multiple myeloma.
Learn more: hubs.ly/Q04l36-j0
#multiplemyeloma #howitreat
46
Updates from #EHA26: Results from a phase 3 study demonstrated that the addition of polatuzumab vedotin to R-ICE did not improve outcomes in relapsed or refractory #LBCL. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
1
79
Updates from #EHA26: Results from an ongoing phase 1 study show that #OL101 produced deep responses in heavily pretreated relapsed or refractory multiple #myeloma. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
71
Results from a phase 2 trial showed that #ACT001 plus #radiotherapy demonstrated encouraging clinical activity in newly diagnosed pediatric diffuse intrinsic pontine #glioma. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
36
Phase 3 #TQB2450III11 results show that #benmelstobart plus #chemo followed by benmelstobart and #anlotinib maintenance significantly improved #PFS in advanced non-squamous NSCLC. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
19
Sara Hurvitz, MD, discusses results from the phase 3 #VIKTORIA1 trial evaluating #gedatolisib-based combinations in previously treated advanced breast cancer. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
37
Phase 3 data showed that triple oral metronomic #chemo plus ultra-low-dose #nivolumab demonstrated promise in recurrent or metastatic head and neck cancers. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
34
Results from #WUKONG28: #Sunvozertinib significantly improved #PFS in treatment-naïve advanced #EGFR-mutated #NSCLC. Learn more: hmpgloballearningnetwork.com…
#medtwtitter #onctwitter
39
Phase 3 #SENOMAC results show omission of axillary lymph node dissection after a positive sentinel lymph node #biopsy did not compromise survival and significantly reduced long-term morbidity in early-stage breast cancer. Learn more: hmpgloballearningnetwork.com…
#medtwitter
49
Updated #RUBY results show durable #PFS benefit with #dostarlimab plus #chemo in dMMR/MSI-H advanced or recurrent #endometrial cancer. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
56
Phase 3 #SUCCESSOR2 results show #mezigdomide plus #carfilzomib and #dexamethasone significantly improved #PFS in relapsed/refractory multiple #myeloma. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
71
Results from #TALAPRO3: #Talazoparib plus #enzalutamide significantly improved #rPFS in #HRR-deficient metastatic castration-sensitive #prostate cancer. Learn more: hmpgloballearningnetwork.com…
#medtwitter #onctwitter
54